Immunostimulatory oligodeoxynucleotides
CA 2411575 C · Owner: Intercell Biomedizinische Forschungs-Und Entwicklungs Ag · Inventors: Egyed, Alena; Schmidt, Walter; Lingnau, Karen
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I) wherein any NMP is a 2' , deoxynucleoside monophosphate or monothiophosphate selected from the group , consisting of deoxyadenosinedeoxyguanosine-, deoxyinosine-, deoxycytosinedeoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine- 5-methyl-deoxycytosine-, deoxypseudouridinedeoxyribosepurine-, 2-amino-deoxyribosepurine- -6-S-, deoxyguanine-, 2-dimethyl-deoxyguanosine- or N- isopentenyl-deoxyadenosinemonophosphate or -monothiophosphate, NUC is a 2' deoxynucleoside selected , from the group consisting of deoxyadenosinedeoxyguanosine-, deoxyinosine-, deoxycytosinedeoxyuridine-, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 7, 2001 and granted April 7, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 7, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 7, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.